2025-2034 Hereditary Angioedema Therapeutics Market Roadmap: Insights for Competitive Advantage

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Hereditary Angioedema Therapeutics Market Size By 2025?
In recent times, there has been a substantial growth in the market size of Hereditary Angioedema therapeutics. It is projected to rise from $6.68 billion in 2024 to $7.84 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 17.3%. Factors such as enhanced diagnosis and awareness, increased accessibility to treatments, initiatives in research and development, patient advocacy and education, and regulatory approvals have contributed to the remarkable growth during the historic period.

How Big Is the Hereditary Angioedema Therapeutics Market Size Expected to Grow by 2029?
The market size for therapeutics in hereditary angioedema is predicted to witness a swift expansion in the coming years. It is projected to reach "$16.11 billion by 2029, with a compound annual growth rate (CAGR) of 19.7%. The market growth during the forecast period is expected to be driven by factors such as advances in targeted therapies, worldwide market growth, progress in gene therapy, trends in personalized medicine, and collaborative efforts in research and treatment. The forecast period will also see significant trends like global access initiatives, research into health economic outcomes, strategies for early intervention, and therapeutics for pediatric HAE.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Key Market Drivers Powering Hereditary Angioedema Therapeutics Market Expansion and Growth?
The increasing occurrence of hereditary angioedema is predicted to boost the expansion of the hereditary angioedema market in the future. Hereditary angioedema, or HAE, is an unusual genetic disease defined by regular instances of extreme swelling in the skin and mucous membranes. This swelling results from an excessive accumulation of fluid, or edema, and can manifest anywhere in the body such as the hands, feet, face, intestines, and airways. As an example, Rare Disease Advisor, an online resource company that caters to healthcare professionals worldwide, reported in June 2022 that globally, there's one hereditary angioedema sufferer for every 50,000 people, with prevalence estimates fluctuating between 1:10,000 and 1:150,000. There are an estimated 15,000 to 30,000 visits to the emergency room each year in the US due to HAE episodes. Around 5.8% of HAE cases had an average diagnosis time between 0 to 6 months, while the same percentage had an average diagnosis time exceeding 10 years. Hence, the escalating occurrence of hereditary angioedema is fueling the development of the hereditary angioedema market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Hereditary Angioedema Therapeutics Market?
Product innovations are becoming increasingly prominent in the hereditary angioedema therapeutics market, where companies are focusing on cutting-edge developments like LICA antisense medicines and gene therapy. In March 2023, US-based Intellia Therapeutics launched NTLA-2002, an Investigational New Drug approved by the US FDA. This in vivo genome editing therapy aims to permanently reduce kallikrein protein activity and prevent hereditary angioedema (HAE) attacks through single-dose gene inactivation of KLKB1 in a Phase 1/2 global trial.

What Are the Emerging Segments in the Hereditary Angioedema Therapeutics Market?
The hereditary angioedema therapeutics market covered in this report is segmented -

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand

Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Who Are the Global Leaders in the Hereditary Angioedema Therapeutics Market?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Which are the Top Profitable Regional Markets for the Hereditary Angioedema Therapeutics Industry?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.